PNC Financial Services Group Inc. Boosts Holdings in DaVita Inc. $DVA

PNC Financial Services Group Inc. lifted its position in DaVita Inc. (NYSE:DVA) by 4.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,831 shares of the company’s stock after acquiring an additional 558 shares during the period. PNC Financial Services Group Inc.’s holdings in DaVita were worth $1,970,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Hantz Financial Services Inc. boosted its position in shares of DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. National Pension Service increased its stake in DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company’s stock worth $30,000 after buying an additional 84 shares in the last quarter. NewEdge Advisors LLC boosted its stake in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Teacher Retirement System of Texas increased its holdings in shares of DaVita by 1.4% in the second quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock worth $954,000 after purchasing an additional 94 shares during the last quarter. Finally, Empirical Finance LLC raised its stake in DaVita by 6.0% during the first quarter. Empirical Finance LLC now owns 2,084 shares of the company’s stock valued at $319,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.5%

Shares of NYSE:DVA opened at $116.70 on Wednesday. The business’s 50 day moving average is $126.94 and its 200 day moving average is $134.99. The stock has a market cap of $8.24 billion, a P/E ratio of 12.02, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13. DaVita Inc. has a 52-week low of $115.39 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The firm had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. During the same quarter in the prior year, the company posted $2.59 earnings per share. DaVita’s quarterly revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

DVA has been the subject of several analyst reports. Zacks Research lowered DaVita from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 30th. TD Cowen dropped their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research note on Monday, November 3rd. Cowen reissued a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Bank of America decreased their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research note on Wednesday, September 10th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $148.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.